These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38646949)

  • 1. Extended interval dosing with ocrelizumab in multiple sclerosis.
    Novak F; Bajwa HM; Østergaard K; Berg JM; Madsen JS; Olsen DA; Urbonaviciute I; Illes Z; Stilund ML; Romme Christensen J; Bramow S; Sellebjerg F; Sejbaek T
    Mult Scler; 2024 Jun; 30(7):847-856. PubMed ID: 38646949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
    Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Meng D; Sacco R; Disanto G; Widmer F; Jacober SLS; Gobbi C; Zecca C
    Mult Scler; 2024 Jun; 30(7):857-867. PubMed ID: 38767224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
    Rodriguez-Mogeda C; van Lierop ZYGJ; van der Pol SMA; Coenen L; Hogenboom L; Kamermans A; Rodriguez E; van Horssen J; van Kempen ZLE; Uitdehaag BMJ; Teunissen CE; Witte ME; Killestein J; de Vries HE
    J Neuroinflammation; 2023 Sep; 20(1):215. PubMed ID: 37752582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
    Rolfes L; Pawlitzki M; Pfeuffer S; Nelke C; Lux A; Pul R; Kleinschnitz C; Kleinschnitz K; Rogall R; Pape K; Bittner S; Zipp F; Warnke C; Goereci Y; Schroeter M; Ingwersen J; Aktas O; Klotz L; Ruck T; Wiendl H; Meuth SG
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34261812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
    Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
    Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
    Bou Rjeily N; Fitzgerald KC; Mowry EM
    Mult Scler; 2024 Feb; 30(2):257-260. PubMed ID: 37942884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
    Zanghì A; Avolio C; Signoriello E; Abbadessa G; Cellerino M; Ferraro D; Messina C; Barone S; Callari G; Tsantes E; Sola P; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Inglese M; D'Amico E
    Neurotherapeutics; 2022 Sep; 19(5):1535-1545. PubMed ID: 36036858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
    Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
    Eur Neurol; 2024; 87(4):203-210. PubMed ID: 38754397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis.
    Schuckmann A; Steffen F; Zipp F; Bittner S; Pape K
    Med; 2023 Jun; 4(6):361-372.e3. PubMed ID: 37236189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
    Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
    Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab for multiple sclerosis.
    Lin M; Zhang J; Zhang Y; Luo J; Shi S
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
    Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
    EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates.
    Rempe T; Elfasi A; Rodriguez E; Vasquez M; Graves J; Kinkel R
    Mult Scler Relat Disord; 2023 Nov; 79():105028. PubMed ID: 37813071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
    Santiago-Setien P; Barquín-Rego C; Hernández-Martínez P; Ezquerra-Marigomez M; Torres-Barquin M; Menéndez-Garcia C; Uriarte F; Jiménez-López Y; Misiego M; Sánchez de la Torre JR; Setien S; Delgado-Alvarado M; Riancho J
    Front Immunol; 2023; 14():1086028. PubMed ID: 36817456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA; van Lierop ZY; Gelissen LM; Hoitsma E; Zeinstra EM; van Rooij LC; van Munster CE; Vennegoor A; Mostert JP; Wokke BH; Kalkers NF; Hoogervorst EL; van Eijk JJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige L; Kloosterziel ME; Arnoldus EP; van Dijk GW; Bouvy WH; Wessels MH; Boonkamp L; Strijbis EM; van Oosten BW; De Jong BA; Lissenberg-Witte BI; Barkhof F; Moraal B; Teunissen CE; Rispens T; Uitdehaag BM; Killestein J; van Kempen ZL
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):392-400. PubMed ID: 37963723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.